Updates on Buyback Offer
Ambit Capital Pvt Ltd ("Manager to the Buyback Offer") has submitted to BSE a copy of Letter of Offer to the Equity Shareholders of Novartis India Ltd ("the Company").27-12-2017
27-12-2017
Novartis drug tasigna is approved by FDA as first and only CML therapy with treatmentfree Remission data in its label
Novartis announced has that the US Food and Drug Administration (FDA) approved the inclusion of Treatmentfree Remission (TFR) data in the Tasigna (nilotinib) US product label. Tasigna is now the first and only BCRABL27-12-2017
Taking healthcare down India interiors' dusty lanes
As Novartis' social business initiative Arogya Parivar' completes 10 years, can it be the model to take healthcare to Bharat?08-12-2017
Updates on Buyback Offer
Ambit Capital Pvt Ltd ("Manager to the Buyback Offer") has submitted to BSE a copy of Draft Letter of Offer for the Buyback Offer by the Novartis India Ltd ("the Company") to its Equity Shareholders.06-12-2017
Australia takes GlaxoSmithKline, Novartis units to court
Misleading representations in marketing of pain relief products06-12-2017
Buyback Offer
Ambit Capital Pvt Ltd ("Manager to the Buyback Offer") has submitted to BSE a copy of Public Announcement for the attention of Equity Shareholders / Beneficial Owners of Equity Shares of Novartis India Ltd ("Target Company") for Buyback of Equity Shares through Tender Offer.27-11-2017
Newspaper Publication
Dear Sirs, Please find enclosed copies of Public Announcement, which has been published in the Financial Express, Jansatta and Navshakti on November 24, 2017, the contents of which are self-explanatory. The same has been made available on the website of the Company www.novartis.in.24-11-2017
Newspaper Publication
Newspaper advertisement of Record Date Intimation for Buyback Dear Sirs, In continuation to our letter dated November 22, 2017, please find enclosed copies of Record date intimation for Buyback of equity, which was shares of Novartis India Limited published in the Financial Express and Navshakti on November 23, 2017. The same has been made available on the website of the Company www.novartis.in.23-11-2017
Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Novartis India Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here22-11-2017